Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.12
(
-0.64%
)
Bitcoin
78,542.28
(
0.00%
)
News Focus
News Focus
Post# of 257484
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

dav1234

Send PM Follow Ignore
Followers 97
Posts 92809
Boards Moderated 4
Alias Born 10/29/2007

dav1234

Re: None

Tuesday, 03/19/2013 6:36:43 PM

Tuesday, March 19, 2013 6:36:43 PM

Post# of 257484
Amgen's T-Vec melanoma drug met primary endpoint in ph3 study, with 16% of patients responding for 6mo vs 2% in GM-CSF arm. $AMGN

Amgen announces top-line results from Phase 3 melanoma trial http://bit.ly/WC5h00
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today